Perhaps too soon to celebrate, but at least it sounds as a good news:

France to provide universal access to hepatitis C treatment

France will provide access to hepatitis C treatment with direct-acting antivirals to everyone diagnosed with hepatitis C from September 2016, and will begin to provide treatment to everyone with stage 2 fibrosis immediately, health minister Marisol Touraine announced last week.

Up to 230,000 people in France with hepatitis C could be treated for hepatitis C under the new rules, the French health ministry has said, but Marisol Touraine said that the prices paid by the French health system for direct-acting antivirals must be renegotiated. The current cost of treatment is around 41,000 euros, and the budget for hepatitis C treatment had been capped at 700 million euros, with Gilead required to pay an unspecified rebate on the cost of sofosbuvir if expenditure rose above this level.

700 000 000 Euro / 230 000 patients ~= 3 000 Euro/treatment -> sounds like a nice dream.

The Comité économique des produits de santé (CEPS) will now pursue a price renegotiation, taking into account recent price agreements in other countries.

The French health minister noted that other European countries had been able to use the French price negotiations to achieve favourable deals for high-volume prescribing. In Spain and Portugal prices of 13,000 euros are believed to have been achieved in confidential deals, in which governments pay nothing for patients who are not cured and the cost of treatment is the same regardless of duration.

More details here:
http://www.eatg.org/news/174296/France_to_provide_universal_access_to_hepatitis_C_treatment